Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy
Machaon M. K. Bonafede, PhD, MPH, Donna McMorrow, BS, Clare Proudfoot, PhD, Shraddha Shinde, MS, MBA, Andreas Kuznik, PhD, Chieh-I Chen, MPH
This retrospective analysis is based on inpatient medical claims, outpatient medical claims, and pharmacy claims from the Truven Health MarketScan Commercial Database. The database includes claims for approximately 35 million employees and their dependents in fee-for-service and managed care health plans.
Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States
Narcolepsy is a chronic, disabling sleep disorder characterized by excessive daytime sleepiness and recurrent periods of sudden, unintentional lapses into sleep during the day. This condition may occur with or without cataplexy, an abrupt and typically bilateral loss of skeletal muscle tone that is often triggered by strong emotion that, when severe, may cause the patient to briefly collapse without losing consciousness.
Accurate Diagnosis of Chronic Diseases Can Reduce Costs and Medical Resource Utilization
Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System
Raghu Durvasula, MD, MHA, Janet Kelly, PharmD, Anneliese Schleyer, MD, MHA, Bradley D. Anawalt, MD, Shabir Somani, MS, MBA, RPh, FASHP, Timothy H. Dellit, MD
Healthcare expenditures in the United States continue to grow at an unprecedented and unsustainable rate. With the shift to value-based care, healthcare organizations are expected to provide consistent high-quality, safe care while reducing healthcare costs.
Pharmacy & Therapeutics Committees’ New Challenge: Stewardship for Specialty Drugs
Effects of Educational Messaging on Urgent and Emergent Care–Seeking Behaviors Among Publicly Insured Populations
Jesse Cambon, MEng, Tristan Cordier, MS, Elizabeth L. Munnich, PhD, MPP, Andrew Renda, MD, Bobby Kapur, MD, MPH, Shkelzen Hoxhaj, MD, MPH, MBA, Meredith Williams, MD, MBA
Narrow network plans offer limited provider choice, but they are attractive to premium-sensitive healthcare consumers, because premiums and out-of-pocket costs are lower than plans with broader provider networks. However, the intended cost-savings for individuals and health
Opportunities to Improve Urgent and Emergent Care Utilization
Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States
Approximately 30,000 new cases of multiple myeloma are diagnosed annually in the United States, and 12,650 deaths annually are attributed to multiple myeloma.
Improved Clinical Outcomes with Newer Multiple Myeloma Therapies Associated with Increased Resource Utilization and Financial Burden
Yuexin Tang, PhD, Xingyue Huang, PhD, Jinan Liu, PhD, R. Ravi Shankar, MD, Michael L. Ganz, PhD, Swapnil Rajpathak, MD, DrPH
Type 2 diabetes mellitus (T2DM) affects approximately 30.3 million individuals in the United States, a number that is expected to grow to almost 36 million by the year 2030.
Impact of Step Therapy Restrictions in Diabetes Care
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors
Rajeev Ayyagari, PhD, Maureen Neary, PhD, MS, Shang Li, MS, Ariel Rokito, BS, Hongbo Yang, PhD, Jipan Xie, MD, PhD, Al B. Benson III, MD, FACP, FASCO
Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers
Burton S. Brodsky, MD, Gary M. Owens, MD, Dennis J. Scotti, PhD, MBA, Keith A. Needham, BS, Christina L. Cool, MPH
Ovarian cancer is the eighth most common cancer among women, but ranks fifth in cancer-related causes of death, the majority of which are detected in late stages, after the cancer has metastasized.
Economic Impact of Using Tests to Guide the Treatment of Patients with Ovarian Cancer
Michael S. Broder, MD, MSHS, Tiffany P. Quock, MS, PhD, Eunice Chang, PhD, Sheila R. Reddy, PhD, RPh, Rajni Agarwal-Hashmi, MD, Sally Arai, MD, Kathleen F. Villa, MS
Cancer is costly. As new cancer therapies become available that extend survival, and as the US population ages and continues to grow, the cost of cancer care is estimated to reach almost $158 billion in 2020, according to the National Cancer Institute.
More Data Analysis Is Needed to Improve Outcomes, Lower Costs, and Maximize Appropriate Resource Use
Costs and Effectiveness of Mindfulness-Based Art Therapy versus Standard Breast Cancer Support Group for Women with Cancer
Katherine M. Prioli, BS, Laura T. Pizzi, PharmD, MPH, Kathryn M. Kash, PhD, Andrew B. Newberg, MD, Anna Marie Morlino, PharmD, Michael Matthews, BS, Daniel A. Monti, MD
The results of several studies have demonstrated that women and men with a cancer diagnosis benefit from interventions to reduce distress and improve quality of life (QOL). However, little is known about the costs and effectiveness of such interventions.
Creative Therapeutic Activities and Support Groups Benefit All Those Involved in Cancer Care
Page 2 of 13
Results 11 - 20 of 125
Results 11 - 20 of 125